[The occurrence of hypersensitivity of a retarded type to IgG cleft by sulfitolysis in patients with different forms of psoriasis (author's transl)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to L Cebecauer.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In NZB mice of different ages (2, 4, 8, 12, and 16 months) the positivity of the migration inhibition test performed with the ds-DNA in spleen explants was compared with the level of immunofluorescent antinuclear antibodies and the incidence of glomerulonephritis. The positivity of the MIT was apparent at 4 months of age, rose with ageing and decreased after 12 months of age. Production of ANA began later, mostly at 8 months of age, increased progressively with ageing, especially in female mice, and was followed by the development of glomerulonephritis which reached its peak at 16 months of age.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A correlation was made between the severity of clinical symptoms of SLE and the results of the migration inhibitory factor (MIF) production test. For this purpose 10 patients with various manifestations of SLE were examined by MIF production test before and after the immunosuppressive therapy. A good correlation between the actual clinical stage and the results of the MIF production test was found. The successful immunosuppressive therapy turned the positive MIF production into the negative one in most of the observed patients. The MIF production test is therefore recommended as a good complementary test for the estimation of the actual state of the SLE.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.